|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Pemafibrate>> Market Analysis Reports |
Market Analysis Reports of Pemafibrate |
|
Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022 This report can be delivered to the clients within 120 Business Hours The global hyperlipidemia drugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the ... Primary Biliary Cirrhosis - Pipeline Review, H2 2018 Primary Biliary Cirrhosis - Pipeline Review, H2 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H2 2018, provides an overview of the Primary Biliary Cirrhosis ( ... Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary ... Dyslipidemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major dyslipidemia markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.8 Billion by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034. The dyslipidemia market has been ... Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034 The 7 major Non-alcoholic fatty liver disease (NAFLD) markets reached a value of US$ 13.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.2% during 2024-2034. The Non- ... Global Primary Biliary Cholangitis Treatment Market - 2025-2033 ... such as Saroglitazar, CNP-104, and Pemafibrate are mostly conducted in the U.S. and ... |